On November 1, 2022 Carisma Therapeutics Inc. (Carisma Therapeutics), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the acceptance of multiple abstracts to be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Anniversary Annual Meeting in Boston, Massachusetts, which is being held November 8 to November 12, 2022 (Press release, Carisma Therapeutics, NOV 1, 2022, View Source [SID1234622744]). Accepted abstracts include: two abstracts of clinical trial data, including one for oral presentation; four abstracts of pre-clinical study data; and one abstract overviewing the design of a Phase 1 clinical trial for CT-0508.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to participate at the SITC (Free SITC Whitepaper) 37th Anniversary Annual Meeting so we can share the latest updates from our landmark CT-0508 trial," said Steven Kelly, Chief Executive Officer of Carisma Therapeutics. "Across the seven abstracts we will be presenting, we are eager to share the promising clinical and pre-clinical updates and the advances within the Carisma Therapeutics pipeline."

Presentation and posters will be available on the SITC (Free SITC Whitepaper) 37th Anniversary Annual Meeting portal for registered attendees. Details of the presentations are as follows:

Oral Presentation:
Title: Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508
Oral Presentation Abstract Number: 315
Date/Time: November 11, 2022, 12:18pm EST – 12:26pm EST
Poster Presentations:
Title: Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy
Poster/Abstract Number: 371
Date: November 10, 2022
Title: A Phase 1, First in Human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.
Poster/Abstract Number: 633
Date: November 10, 2022
Title: A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors.
Poster/Abstract Number: 634
Date: November 11, 2022
Title: Macrophages Engineered to Express Synthetic Cytokine Switch Receptors Act as Living Microenvironment Converters
Poster/Abstract Number: 376
Date: November 11, 2022
Title: Pre-clinical development of a CAR Monocyte platform for cancer immunotherapy
Poster/Abstract Number: 318
Date: November 11, 2022
Title: Pre-clinical development of CT-1119, a mesothelin targeting chimeric antigen receptor macrophage (CAR-M), for solid tumor immunotherapy
Poster/Abstract Number: 194
Date: November 11, 2022